Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis

British Journal of Surgery

Volumn 103, Issue 4, 2016, Pages 417-426

  Orci, L A ^a,b   Lacotte, S ^a   Oldani, G ^a,b   Slits, F ^a   De Vito, C ^a,b   Crowe, L A ^a   Rubbia Brandt, L ^a,b   Vallee J P ^a   Morel, P ^a,b   Toso, C ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hepato pancreato biliary Centre   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TUMOR MARKER;

ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CELL MOTION; CELL PROLIFERATION; EXPERIMENTAL NEOPLASM; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; ISCHEMIC PRECONDITIONING; LIVER NEOPLASMS; MALE; MOUSE; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA, NEOPLASM; FATTY LIVER; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; ISCHEMIC PRECONDITIONING; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84966642539     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.10080     Document Type: Article

References (30)

1. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
2. Adam R, Bhangui P, Vibert E, Azoulay D, Pelletier G, Duclos-Vallée JC, et al. Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg 2012; 256: 883-891.
3. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009; 137: 850-855.
4. Davis E, Wiesner R, Valdecasas J, Kita Y, Rossi M, Schwartz M,. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2011; 17 (Suppl 2): S162-S166.
5. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994.
6. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
7. Orci LA, Lacotte S, Oldani G, Morel P, Mentha G, Toso C,. The role of hepatic ischemia-reperfusion injury and liver parenchymal quality on cancer recurrence. Dig Dis Sci 2014; 59: 2058-2068.
8. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O,. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46.
9. Nativ NI, Maguire TJ, Yarmush G, Brasaemle DL, Henry SD, Guarrera JV, et al. Liver defatting: an alternative approach to enable steatotic liver transplantation. Am J Transplant 2012; 12: 3176-3183.
10. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993; 55: 807-813.
11. Degli Esposti D, Sebagh M, Pham P, Reffas M, Poüs C, Brenner C, et al. Ischemic preconditioning induces autophagy and limits necrosis in human recipients of fatty liver grafts, decreasing the incidence of rejection episodes. Cell Death Dis 2011; 2: e111.
12. Selzner N, Selzner M, Jochum W, Clavien PA,. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. J Hepatol 2003; 39: 55-61.
13. Serafin A, Rosello-Catafau J, Prats N, Xaus C, Gelpi E, Peralta C,. Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia-reperfusion injury in the rat. Am J Pathol 2002; 161: 587-601.
14. Oldani G, Crowe LA, Orci LA, Slits F, Rubbia-Brandt L, de Vito C, et al. Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation. J Hepatol 2014; 61: 278-285.
15. Orci LA, Berney T, Majno PE, Lacotte S, Oldani G, Morel P, et al. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation. Br J Surg 2015; 102: 1250-1257.
16. Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, et al. Ischemia time impacts recurrence of hepatocellular carcinoma following liver transplantation. Hepatology 2015; 61: 895-904.
17. Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R,. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl 2013; 19: 1214-1223.
18. Jay C, Ladner D, Wang E, Lyuksemburg V, Kang R, Chang Y, et al,. A comprehensive risk assessment of mortality following donation after cardiac death liver transplant-an analysis of the national registry. J Hepatol 2011; 55: 808-813.
19. Nijkamp MW, van der Bilt JD, Snoeren N, Hoogwater FJ, van Houdt WJ, Molenaar IQ, et al. Prolonged portal triad clamping during liver surgery for colorectal liver metastases is associated with decreased time to hepatic tumour recurrence. Eur J Surg Oncol 2010; 36: 182-188.
20. Yang Y, Fu SY, Lau WY, Lai E, Li AJ, Pan ZY, et al. Selective main portal vein clamping to minimize the risk of recurrence after curative liver resection for hepatocellular carcinoma. Hepatogastroenterology 2012; 59: 1560-1565.
21. Makino I, Chijiiwa K, Kondo K, Ohuchida J, Kai M,. Prognostic benefit of selective portal vein occlusion during hepatic resection for hepatocellular carcinoma. Surgery 2005; 137: 626-631.
22. Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, et al. Ischemia-reperfusion of small liver remnant promotes liver tumour growth and metastases-activation of cell invasion and migration pathways. Liver Transpl 2007; 13: 1669-1677.
23. Doi K, Horiuchi T, Uchinami M, Tabo T, Kimura N, Yokomachi J, et al. Hepatic ischemia-reperfusion promotes liver metastasis of colon cancer. J Surg Res 2002; 105: 243-247.
24. Leung CH, Caldarone CA, Wang F, Venkateswaran S, Ailenberg M, Vadasz B, et al. Remote ischemic conditioning prevents lung and liver injury after hemorrhagic shock/resuscitation: potential role of a humoral plasma factor. Ann Surg 2015; 261: 1215-1225.
25. van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, Te Velde EA, et al,. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005; 42: 165-175.
26. Qi Q, Bie P,. Different roles of hepatic hypothermic ischemia and ischemic preconditioning in chemically induced hepatocarcinogenesis in rats. J Surg Res 2014; 189: 213-221.
27. Michelotti GA, Machado MV, Diehl AM,. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-665.
28. Selzner N, Selzner M, Jochum W, Amann-Vesti B, Graf R, Clavien PA,. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol 2006; 44: 694-701.
29. Lacotte S, Oldani G, Slits F, Orci LA, Rubbia-Brandt L, Morel P, et al. Alloimmune activation promotes anti-cancer cytotoxicity after rat liver transplantation. PloS One 2014; 9: e91515.
30. Lee JH, Lee JH, Lim Y, Yeon J, Song T, Yu SJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148: 1383-1391.